Skip to main content
SpringerLink
Log in

Contribution of angiotensin-(1-7) to cardiovascular physiology and pathology

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Increased understanding of the contribution of angiotensin peptides to the physiologic control of arterial pressure and cardiovascular regulation has been made possible with the introduction of agents that either inhibit the activity of angiotensins forming enzymes or block the action of the peptides at their specific receptor subtypes. This review highlights some of the lessons that have been learned from the study of the actions of angiotensin-(1-7) and its interrelationship with other vasodilator mechanisms that modulate the control systems that determine blood pressure and tissue perfusion. The studies suggest that the reninangiotensin system acts as a humoral mechanism for blood pressure control through the generation of several distinct forms of angiotensin peptides that may bind to diverse receptor subtypes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Page IH: The mosaic theory of hypertension. In Essential Hypertension. Edited by Bock KD, Cottier PT. Berlin: Springer Verlag; 1960:1–29.

    Google Scholar 

  2. Lawrence AC, Clark IJ, Campbell DJ: Increased angiotensin-(1–7) in hypophysial-portal plasma of conscious sheep. Neuroendocrinology 1992, 55:105–114.

    PubMed  CAS  Google Scholar 

  3. Chappell MC, Pirro NT, Sykes A, Ferrario CM: Metabolism of angiotensin-(1–7) by angiotensin converting enzyme. Hypertension 1998, 31:362–367. First demonstration of the hydrolysis of Ang-(1–7) by ACE.

    PubMed  CAS  Google Scholar 

  4. Yamada K, Iyer SN, Chappell MC, et al.: Converting enzyme determines the plasma clearance of angiotensin-(1–7). Hypertension 1998, 98:496–502.

    Google Scholar 

  5. Welches WR, Brosnihan KB, Ferrario CM: A comparison of the properties, and enzymatic activity of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. Life Sci 1993, 52:1461–1480.

    Article  PubMed  CAS  Google Scholar 

  6. Shariat-Madar Z, Mahdi F, Schmaier AH: Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem 2002, 277:17962–17969.

    Article  PubMed  CAS  Google Scholar 

  7. Crackower MA, Sarao R, Oudit GY, et al.: Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002, 417:822–828. This study characterizes the existence of an ACE homolog (ACE-2) that is not inhibited by ACE inhibitors and is capable of generating Ang-(1–7) from Ang II.

    Article  PubMed  CAS  Google Scholar 

  8. Vickers C, Hales P, Kaushik V, et al.: Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 2002, 277:14838–14843.

    Article  PubMed  CAS  Google Scholar 

  9. Donoghue M, Hsieh F, Baronas E, et al.: A novel angiotensinconverting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ Res 2000, 87:E1-E9.

    PubMed  CAS  Google Scholar 

  10. Chappell MC, Jung F, Gallagher PE, et al.: Omapatrilat treatment is associated with increased ACE-2 and angiotensin-(1–7) in spontaneously hypertensive rats. Hypertension 2002, 40:409.

    Google Scholar 

  11. Urata H, Kinoshita A, Misono KS, et al.: Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990, 265:22348–22357.

    PubMed  CAS  Google Scholar 

  12. Ferrario CM, Brosnihan KB, Diz DI, et al.: Angiotensin-(1–7): a new hormone of the angiotensin system. Hypertension 1991, 18(Suppl III):III126-III133.

    PubMed  CAS  Google Scholar 

  13. Li P, Chappell MC, Ferrario CM, Brosnihan KB: Angiotensin-(1–7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension 1997, 29:394–400.

    PubMed  CAS  Google Scholar 

  14. Ren Y, Garvin JL, Carretero OA: Vasodilator action of angiotensin-(1–7) on isolated rabbit afferent arterioles. Hypertension 2002, 39:799–802.

    Article  PubMed  CAS  Google Scholar 

  15. Santos RAS, Campagnole-Santos MJ, Andrade SP: Angiotensin-(1–7): an update. Regul Pept 2000, 91:45–62. This review provides a detailed analysis of the mechanisms that underline the potentiating effects of Ang-(1–7) on bradykinin.

    Article  PubMed  CAS  Google Scholar 

  16. Benter IF, Diz DI, Ferrario CM: Cardiovascular actions of angiotensin-(1–7). Peptides 1993, 14:679–684.

    Article  PubMed  CAS  Google Scholar 

  17. Luque M, Martin P, Martell N, et al.: Effects of captopril related to increased levels of prostacyclin and angiotensin-(1–7) in essential hypertension. J Hypertens 1996, 14:799–805.

    Article  PubMed  CAS  Google Scholar 

  18. Machado RD, Ferreira MA, Belo AV, et al.: Vasodilator effect of angiotensin-(1–7) in mature and sponge-induced neovasculature. Regul Pept 2002, 107:105–113.

    Article  PubMed  CAS  Google Scholar 

  19. Machado RD, Santos RA, Andrade SP: Mechanisms of angiotensin-(1–7)-induced inhibition of angiogenesis. Am J Physiol Regul Integr Compar Physiol 2001, 280:R994-R1000.

    CAS  Google Scholar 

  20. Nakamoto H, Ferrario CM, Fuller SB, et al.: Angiotensin-(1–7) and nitric oxide interaction in renovascular hypertension. Hypertension 1995, 25:796–802.

    PubMed  CAS  Google Scholar 

  21. Iyer SN, Averill DB, Chappell MC, et al.: Contribution of angiotensin-(1–7) to blood pressure regulation in saltdepleted hypertensive rats. Hypertension 2000, 36:417–422. This study in rats illustrates the contribution of Ang-(1–7) to the regulation of blood pressure in a situation in which salt depletion increases the activity of the renin-angiotensin system.

    PubMed  CAS  Google Scholar 

  22. Iyer SN, Chappell MC, Averill DB, et al.: Vasodepressor actions of angiotensin-(1–7) unmasked during combined treatment with lisinopril and losartan. Hypertension 1998, 31:699–705.

    PubMed  CAS  Google Scholar 

  23. Iyer SN, Ferrario CM, Chappell MC: Angiotensin-(1–7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension 1998, 31:356–361.

    PubMed  CAS  Google Scholar 

  24. Paula RD, Lima CV, Khosla MC, Santos RAS: Angiotensin-(1–7) potentiates the hypotensive effect of bradykinin in conscious rats. Hypertension 1995, 26:1154–1159.

    PubMed  CAS  Google Scholar 

  25. Paula RD, Lima CV, Britto RR, et al.: Potentiation of the hypotensive effect of bradykinin by angiotensin-(1–7)-related peptides. Peptides 1999, 20:493–500.

    Article  PubMed  CAS  Google Scholar 

  26. Gorelik G, Carbini LA, Scicli AG: Angiotensin 1-7 induces bradykinin-mediated relaxation in porcine coronary artery. J Pharmacol Exp Ther 1998, 286:403–410.

    PubMed  CAS  Google Scholar 

  27. Fernandes L, Fortes ZB, Nigro D, et al.: Potentiation of bradykinin by angiotensin-(1–7) on arterioles of spontaneously hypertensive rats studied in vivo. Hypertension 2001, 37:703–709.

    PubMed  CAS  Google Scholar 

  28. Neves LA, Almeida AP, Khosla MC, Santos RA: Metabolism of angiotensin I in isolated rat hearts. Effect of angiotensin converting enzyme inhibitors. Biochem Pharmacol 1995, 50:1451–1459.

    Article  PubMed  CAS  Google Scholar 

  29. Ueda S, Masumori-Maemoto S, Wada A, et al.: Angiotensin (1–7) potentiates bradykinin-induced vasodilatation in man. J Hypertens 2001, 19:2001–2009.

    Article  PubMed  CAS  Google Scholar 

  30. Oliveira MA, Fortes ZB, Santos RA, et al.: Synergistic effect of angiotensin-(1–7) on bradykinin arteriolar dilation in vivo. Peptides 1999, 20:1195–1201.

    Article  PubMed  CAS  Google Scholar 

  31. Almeida AP, Frabregas BC, Madureira MM, et al.: Angiotensin-(1–7) potentiates the coronary vasodilatatory effect of bradykinin in the isolated rat heart. Braz J Med Biol Res 2000, 33:709–713.

    PubMed  CAS  Google Scholar 

  32. Deddish PA, Marcic B, Jackman HL, et al.: N-domain specific substrate and C-domain inhibitors of angiotensin converting enzyme. Hypertension 1998, 31:912–917.

    PubMed  CAS  Google Scholar 

  33. Tom B, deVries R, Saxena PR, Danser AH: Bradykinin potentiation by angiotensin-(1–7) and ACE inhibitors correlates with ACE C- and N-domain blockade. Hypertension 2001, 38:95–99.

    PubMed  CAS  Google Scholar 

  34. Benzing T, Fleming I, Blaukat A, et al.: Angiotensin-converting enzyme inhibitor ramiprilat interferes with the sequestration of the B2 kinin receptor within the plasma membrane of native endothelial cells. Circulation 1999, 99:2034–2040.

    PubMed  CAS  Google Scholar 

  35. Strawn WB, Chappell MC, Dean RH, et al.: Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation 2000, 101:1586–1593.

    PubMed  CAS  Google Scholar 

  36. Strawn WB, Ferrario CM, Tallant EA: Angiotensin-(1–7) reduces smooth muscle growth after vascular injury. Hypertension 1999, 33:207–211.

    PubMed  CAS  Google Scholar 

  37. Yoshida M, Naito Y, Urano T, et al.: L-158,809 and (D-Ala(7))-angiotensin I/II (1–7) decrease PAI-1 release from human umbilical vein endothelial cells. Thromb Res 2002, 105:531–536.

    Article  PubMed  CAS  Google Scholar 

  38. Suzuki H, Smeby RR, Mikami H, et al.: Nonrenal factors contribute to plasma and cerebrospinal fluid angiotensin II. Hypertension 1986, 8(Suppl I):I95-I100.

    CAS  Google Scholar 

  39. Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995–1003.

    Article  PubMed  CAS  Google Scholar 

  40. Yusuf S: From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 2002, 89(Suppl):18A-26A.

    Article  PubMed  Google Scholar 

  41. Carey RM, Jin XH, Siragy HM: Role of the angiotensin AT2 receptor in blood pressure regulation and therapeutic implications. Am J Hypertens 2001, 14:98S-102S.

    Article  PubMed  CAS  Google Scholar 

  42. AbdAlla S, Lother H, Abdel-tawab AM, Quitterer U: The angiotensin II AT2 receptor is an AT1 receptor antagonist. J Biol Chem 2001, 276:39721–39726.

    Article  PubMed  CAS  Google Scholar 

  43. Yamada K, Iyer SN, Chappell MC, et al.: Differential response of angiotensin peptides in the urine of hypertensive animals. Regul Pept 1999, 80:57–66.

    Article  PubMed  CAS  Google Scholar 

  44. Benter IF, Ferrario CM, Morris M, Diz DI: Antihypertensive actions of angiotensin-(I–7) in spontaneously hypertensive rats. Am J Physiol 1995, 269:H313-H319.

    PubMed  CAS  Google Scholar 

  45. Burnett JCJ: Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens 1999, 17(Suppl):S37-S43.

    CAS  Google Scholar 

  46. Ferrario CM, Smith RD, Brosnihan KB, et al.: Effects of omapatrilat on the renin angiotensin system in salt sensitive hypertension. Am J Hyperten 2002, 15:557–564.

    Article  CAS  Google Scholar 

  47. Ferrario CM, Averill DB, Brosnihan KB, et al.: Vasopeptidase inhibition and Ang-(1–7) in the spontaneously hypertensive rat. Kidney Int 2002, 62:1349–1357.

    Article  PubMed  CAS  Google Scholar 

  48. Valdes G, Germain AM, Corthorn J, et al.: Urinary vasodilator and vasoconstrictor angiotensins during menstrual cycle, pregnancy, and lactation. Endocrine 2001, 16:117–122.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hypertension and Vascular Disease Center, Wake Forest University Health Science Center, 27157, Winston-Salem, NC, USA

    Carlos M. Ferrario MD, FACA, FACC

Authors
  1. Carlos M. Ferrario MD, FACA, FACC
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ferrario, C.M. Contribution of angiotensin-(1-7) to cardiovascular physiology and pathology. Current Science Inc 5, 129–134 (2003). https://doi.org/10.1007/s11906-003-0069-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-003-0069-y

Keywords

Search

Navigation